cd38 inhibitor and 5-amino-1mq synergy nad+ as theranostic target in oncology | Journal of Translational Medicine CD38 as a Regulator of
CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions PMC SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism CD38 Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+ Lowering Agents New Insights on Muscle Strength: The Role of Inhibiting an Enzyme that Hinders NAD+ Synthesis
Pay in 4 interest-free payments of $5.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14



